151 related articles for article (PubMed ID: 38332190)
1. Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension.
Brussee JM; Sidharta PN; Dingemanse J; Krause A
J Pharmacokinet Pharmacodyn; 2024 Jun; 51(3):243-252. PubMed ID: 38332190
[TBL] [Abstract][Full Text] [Related]
2. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.
Sidharta PN; Ulč I; Dingemanse J
Clin Drug Investig; 2019 Nov; 39(11):1117-1123. PubMed ID: 31435905
[TBL] [Abstract][Full Text] [Related]
3. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
Sidharta PN; Melchior M; Kankam MK; Dingemanse J
Drug Des Devel Ther; 2019; 13():949-964. PubMed ID: 30962677
[TBL] [Abstract][Full Text] [Related]
4. Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects.
Fontes MSC; Dingemanse J; Sidharta PN
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):718-725. PubMed ID: 33063477
[TBL] [Abstract][Full Text] [Related]
5. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
Sidharta PN; Dingemanse J
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):995-1002. PubMed ID: 32592633
[TBL] [Abstract][Full Text] [Related]
6. A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension.
Bartolucci R; Dosne AG; Csonka D; Pérez-Ruixo JJ; Magni P; Poggesi I
Clin Pharmacokinet; 2021 Dec; 60(12):1605-1619. PubMed ID: 34159557
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension.
Trensz F; Bortolamiol C; Kramberg M; Wanner D; Hadana H; Rey M; Strasser DS; Delahaye S; Hess P; Vezzali E; Mentzel U; Ménard J; Clozel M; Iglarz M
J Pharmacol Exp Ther; 2019 Mar; 368(3):462-473. PubMed ID: 30622171
[TBL] [Abstract][Full Text] [Related]
8. Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension.
Verweij P; Danaietash P; Flamion B; Ménard J; Bellet M
Hypertension; 2020 Apr; 75(4):956-965. PubMed ID: 32063059
[TBL] [Abstract][Full Text] [Related]
9. Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment.
Fontes MSC; Dingemanse J; Halabi A; Tomaszewska-Kiecana M; Sidharta PN
Sci Rep; 2022 Nov; 12(1):19067. PubMed ID: 36352054
[TBL] [Abstract][Full Text] [Related]
10. Effect of Multiple-Dose Aprocitentan Administration on the Pharmacokinetics of Midazolam in Healthy Male Subjects.
Sidharta PN; Dingemanse J
Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):227-234. PubMed ID: 31773427
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects.
Ahn LY; Kim SE; Yi S; Dingemanse J; Lim KS; Jang IJ; Yu KS
Am J Cardiovasc Drugs; 2014 Oct; 14(5):377-85. PubMed ID: 24906252
[TBL] [Abstract][Full Text] [Related]
12. Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet.
Gueneau de Mussy P; Sidharta PN; Wuerzner G; Maillard MP; Guérard N; Iglarz M; Flamion B; Dingemanse J; Burnier M
Clin Pharmacol Ther; 2021 Mar; 109(3):746-753. PubMed ID: 32897570
[TBL] [Abstract][Full Text] [Related]
13. Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans.
Sidharta PN; Fischer H; Dingemanse J
Curr Drug Metab; 2021; 22(5):399-410. PubMed ID: 33563190
[TBL] [Abstract][Full Text] [Related]
14. Aprocitentan and the endothelin system in resistant hypertension.
Clozel M
Can J Physiol Pharmacol; 2022 Jul; 100(7):573-583. PubMed ID: 35245103
[TBL] [Abstract][Full Text] [Related]
15. Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: Mechanism of action and therapeutic potential.
Xu J; Jiang X; Xu S
Drug Discov Today; 2023 Nov; 28(11):103788. PubMed ID: 37742911
[TBL] [Abstract][Full Text] [Related]
16. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
Schlaich MP; Bellet M; Weber MA; Danaietash P; Bakris GL; Flack JM; Dreier RF; Sassi-Sayadi M; Haskell LP; Narkiewicz K; Wang JG;
Lancet; 2022 Dec; 400(10367):1927-1937. PubMed ID: 36356632
[TBL] [Abstract][Full Text] [Related]
17. Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists.
Volz AK; Dingemanse J; Krause A; Lehr T
Pharm Res; 2019 Dec; 37(1):2. PubMed ID: 31823033
[TBL] [Abstract][Full Text] [Related]
18. Aprocitentan: A new development of resistant hypertension.
Yao Y; Fan B; Yang B; Jia Z; Li B
J Clin Hypertens (Greenwich); 2023 Jul; 25(7):587-590. PubMed ID: 37334561
[TBL] [Abstract][Full Text] [Related]
19. New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis.
Mahfooz K; Najeed S; Tun HN; Khamosh M; Grewal D; Hussain A; Ong K; Dharmarajan L; Vasavada A
Curr Probl Cardiol; 2023 Jul; 48(7):101686. PubMed ID: 36893968
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
Dingemanse J; van Giersbergen PL
Clin Pharmacokinet; 2004; 43(15):1089-115. PubMed ID: 15568889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]